Update on the Observational Gastroenteropancreatic Neuroendocrine Tumors (GEPNET) Registry: An International Collaboration Abstract #505

Introduction: Awareness of, and epidemiologic data for, GEPNETs is lacking in many geographic areas.
Aim(s): To study prevalence, incidence, regional trends in diagnosis, and clinical management of GEPNET in the Asia-Pacific, Middle East, Turkey and South Africa.
Materials and methods: Patients (pts) with histopathological diagnosis of GEPNETs within five yrs before registry entry were included. Pro- and retrospective data were collected at 82 sites. Enrollment began in Jul-09 and is ongoing. Follow-up will be for five yrs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Cassandra A Slader
Keywords: gep-net

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1563 Impact of Early Surgery on Prognosis in Advanced Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)
Introduction: In gastro-entero-pancreatic neuroendocrine tumours (GEP-NET) the role of surgery remains to be determined.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: MD Patrizia Kump
#390 An Increasing Incidence of GEP-NETs in Chengdu City with a Population of 14 Million in China
Introduction: The annual incidence of GEP-NETs in China is still unclear. All histopathology and cytopathology reports have yet to be collected in a national archive. No national or regional survey on GEP-NETs has been approved. West China Hospital (WCH), a university hospital located in Chengdu City with a population of 14 million, has established a series of databases in recent years.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Professor Tang Chengwei
Authors: Guo L, Wang C, Liu W, Zhong M, ...
#1059 Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in Precision-Medicine Era
Introduction: We have conducted molecular profiling through high-throughput molecular test as part of clinical practice for patients with advanced gastrointestinal (GI) cancer, or rare cancer including gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Seung Kim
Authors: Kim S, Yoo K, Jung K, Lee S, ...
#1303 Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals
Introduction: Lanreotide depot (LAN) was recently approved by the FDA to treat mGEP-NETs to improve progression-free survival.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: George Camba
Authors: Ortendahl J, Pulgar S, Cox D, Bentley T, ...
#1810 FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS
Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Ana Paula Santos